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ABSTRACT | Optic neuritis is an inflammatory optic neuropathy that affects many patients with multiple sclerosis (MS) at 
some point during their disease course. Differentiation of acute episodes of MS-associated optic neuritis from other 
autoimmune and inflammatory optic neuropathies is vital for treatment choice and further patient management, but is not 
always straightforward. Over the past decade, a number of new imaging, laboratory and electrophysiological techniques 
have entered the clinical arena. To date, however, no consensus guidelines have been devised to specify how and when 
these techniques can be most rationally applied for the diagnostic work-up of patients with acute optic neuritis. In this 
article, we review the literature and attempt to formulate a consensus for the investigation of patients with acute optic 
neuritis, both in standard care and in research with relevance to clinical treatment trials. 
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Introduction 
Optic neuritis is characterized by inflammation of the optic nerve, and is frequently but not always associated with 
multiple sclerosis (MS).1 Once a patient is diagnosed with MS, visual symptoms may be summarily attributed to a MS 
relapse, potentially missing other treatable aetiologies of visual loss. Transient problems such as conduction block might 
be mistaken for relapses of optic neuritis,2,3 and problems related to impaired eye movements may be overlooked.4–6 
Patients with forms of optic neuritis other than MS-associated optic neuritis (MSON)—including neuromyelitis optica 
(NMO) spectrum disorder and chronic relapsing inflammatory optic neuropathy (CRION)—must be recognized as early 
as possible, because these individuals are at risk of severe visual loss.7,8 
In this Review, we emphasize that optic neuritis represents a pragmatic model for testing structural–functional 
relationships.9,10 The visual system is the best-understood and most accessible part of the human CNS. In each eye, 100 
million rod photoreceptors capture light, which is then converted by 12 types of bipolar cell into a digitally coded electrical 
signal,11 which passes through the 1,158,000 axons of the optic nerve.12 The nerve fibres decussate partially at the optic 
chiasm, synapse in the lateral geniculate nucleus, and finally project through the optic radiations into the well-defined 
cytoarchitecture of the visual cortex,13 wherein plastic capabilities continuously shape our subjective visual experience.14 
A real opportunity exists to make use of this detailed knowledge in an increasingly complex diagnostic and therapeutic 
landscape. 
Table 1 summarizes the published criteria for a single episode of isolated optic neuritis (ION),15 relapsing 
episodes of isolated optic neuritis (RION),15 CRION,7 MSON,16 and optic neuritis as observed in NMO spectrum 
disorder.8 No consensus has been reached on how to investigate patients who present with acute optic neuritis, and this 
Review aims to contribute to the development of such a consensus. Protocols for standard care and research 
(Supplementary Figure  1 online) should take associated costs and resources into account. 
 
History taking 
A structured history-taking process should search for warning signs (‘red flags’) that suggest an alternative diagnosis to 
MSON (Box 1), thereby prompting further investigations. 
The classic clinical presentation of optic neuritis consists of (peri)ocular pain, often retrobulbar, which frequently 
precedes loss of vision and is typically associated with dyschromatopsia. Pain that is exacerbated by eye movement 
suggests inflammation of the optic nerve adjacent to the ocular muscles.17 Ocular pain or headache not worsened on eye 
movement, or painless optic neuritis, may indicate inflammation within the optic canal or intracranial space. In addition, 
positive phenomena such as phosphenes and scintillations can be present. 
Following recovery from optic neuritis, patients might experience glare disability, reduced vision in bright light, 
visual fading, and/or the Uhthoff or Pulfrich phenomenon. 
 
Uhthoff phenomenon 
The symptoms and signs of optic neuritis can be aggravated by a rise in body temperature due to exercise, taking a bath, 
fever due to infection, warm meals, cognitive and/ or emotional stress, or high ambient temperatures. This so-called 
‘Uhthoff phenomenon’ is caused by transient conduction block, and is typically observed during the recovery phase of 
optic neuritis.2,3 
 
Pulfrich phenomenon 
Perception of movement in depth may be difficult following optic neuritis  - a condition termed the Pulfrich phenom 
enon.18,19 Patients might report problems with judging the course of vehicles or bicycles in moving traffic, pouring liquid 
into jars, or judging the trajectory of a tennis or squash ball. We specifically ask whether these problems also occur if the 
patient is not moving, with best corrected visual acuity under binocular viewing conditions. The Pulfrich phenomenon is 
usually found in patients who have recovered from optic neuritis and exhibit good visual acuity, rather than in the acute-
situation. 
 
Clinical and bedside assessment  
Standard care protocol 
An example of the diagnostic work-up for a patient with Key points optic neuritis is presented in Supplementary Figure1 
online and Box 2.  
The standard of care for optic neuritis includes measurement of best corrected high-contrast visual acuity, 
preferably with a LogMAR retroilluminated chart. For conversion of the various acuity tests used around the world to a 
LogMAR value, see Supplementary Table 1 online. 
 In each patient, retinal examination should be performed by direct and indirect ophthalmoscopy. A pale optic 
disc, as shown in Figure 1a, is indicative of optic atrophy.  
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Monocular visual fields can be assessed clinically by confrontation using either finger movements or 
differentially sized and coloured objects.1 We use a 4 mm red pin and also test for red desaturation as an indicator of 
impaired colour vision. Testing for red desaturation can be performed by comparing central vision either between the two 
eyes (affected and unaffected) or regionally within different areas of the visual field of one affected eye.  
We acknowledge that formal perimetry such as the SITA 24-2 protocol would be considered standard care in a 
well-equipped neuro-ophthalmological service, but might not readily be available in a routine neurological outpatient 
department, and may not be well tolerated by all patients.  
The swinging light test should be used to search for a relative afferent pupillary defect (RAPD, also known as 
Marcus Gunn pupil). The RAPD can be amplified by holding a 0.3 log unit neutral density filter in front of the affected 
eye.20 An RAPD should be present in cases of unilateral optic neuritis, but can be absent in binocular simultaneous or 
sequential optic neuritis. If no RAPD is detected, a diagnosis can only be made with extreme caution. The test cannot be 
used if the optic neuropathy is bilateral and symmetrical.  
Pain on eye movements is one of the strongest indicators of optic neuritis, and the few other conditions that 
manifest with this symptom—for example, myositis, orbital inflammation or subtarsal foreign body—can generally be 
excluded at the bedside by testing eyelid function and eye movements. Eye movements are best tested if the patient has 
sufficient visual acuity to focus on an appropriately moving target. We examine smooth pursuit, saccades and vergence 
movements binocularly. We are looking particularly for evidence of slow adduction of one or both eyes on examination of 
horizontal saccades as evidence of subclinical internuclear ophthalmoplegia, which is highly suggestive of demyelination 
elsewhere in the CNS.21 The cover–uncover test helps us to identify transient visual problems that might be attributable 
to a phoria. 
 
Research protocol  
Additional tests that are not routinely used because of time and financial constraints can be incorporated into research 
protocols for optic neuritis. Low-contrast visual acuity can be tested with best correction using Sloan charts.22 In addition, 
Pelli–Robson charts are useful for testing contrast sensitivity. Colour vision tests include, among others, the Ishihara 
Test, the Hardy–Rand–Ritter Pseudoisochromatic Plates, the Lanthony Desaturated D-15 Test or, if time permits, the 
Farnsworth–Munsell 100 Hue Test. Both low-contrast acuity and colour vision tests are sensitive for subtle impairment of 
visual function even years after the episode. Computerized testing of colour vision provides quantitative data.23 
Importantly, this approach also considers relevant age-adjusted normal limits of colour vision, which are required for 
reliable recognition of acquired problems.23 
Patients with the Pulfrich phenomenon can be assessed using a classic pendulum.18,19 A horizontal swinging 
pendulum is perceived as following an ellipsoid trajectory by patients who exhibit this symptom.24 The Pulfrich 
phenomenon is best assessed if the pendulum swings in front of a high-contrast patterned background, which enhances 
binocular disparity (stereoscopic vision).  
 
Optical coherence tomography  
Overview   
Retinal optical coherence tomography (OCT) permits accurate documentation of changes in thickness of retinal 
layers.25,26 The full spectrum of retinal pathology that might be unravelled through the use of OCT in MS is not yet known, 
and new differential diagnoses are being added as the quality of OCT data improves. At present, recommendations for 
standard care and research protocols for optic neuritis are based largely on two types of pathology. First, thinning or 
atrophy of the inner retinal layers—that is, the retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL, Figures 1, 2 
and 3)—is commonly observed. Second, thicke ning or swelling of the peripapillary RNFL can be seen in cases with optic 
disc swelling. There might also be localized thickening of the inner nuclear layer (INL), which can be associated with 
microcystic macular oedema (MMO, also known as microcystic macular changes or retrograde maculopathy;27–29  Figure 
4 and Supplementary Video 1 online). 
 
Thinning  
Loss of the unmyelinated axons in the retina can readily be quantified by OCT, and is understood to represent several 
processes:30 first, pathology in the retinal layers resulting in anterograde (Wallerian) degeneration, leading to thinning of 
the RNFL; second, pathology of the optic nerve, such as an acute optic neuritis attack, causing axonal transection and 
loss (direct retrograde degeneration); and third, posterior visual pathway lesions that lead to thinning of the RNFL by 
trans- synaptic (via the lateral geniculate nucleus) retrograde axonal degeneration. 9,31,32 In reality, axonotemesis in the 
hard-wired visual pathways will always lead to bidirectional transsynaptic axonal degeneration.33 One should allow a 3-
month interval after an acute attack of optic neuritis before attempting to quantify peripapillary atrophy of the RNFL.34,35 
Wedge-like thinning should prompt investigation for vascular pathology, such as AION or Susac syndrome (Table 2).36 
Occasionally, fluor escein angio graphy (FAG; Figure 1b) may be required to further assess retinal blood flow and 
leakage.37 RNFL and GCL atrophy is more severe in NMO and CRION than in MSON.38–43 Caution is required when 
interpreting data from patients with recurrent episodes, as more-severe thinning may be the result of cumulative damage. 
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Thickening 
Disk swelling in the acute phase of optic neuritis is well recognized.1,35 Recent evidence indicates that MMO and 
thickening of the INL are more frequent in NMO than in MSON.44,45 Because of the association between MMO and NMO, 
we advocate testing for the presence of anti-aquaporin 4 antibodies (AQP4-IgG) in patients with MMO who experience 
relapsing optic neuritis, or in the presence of red flags (Box 1, Supplementary Figure 1 online). MMO is not specific for 
either MS or NMO, and is also seen in RION, CRION and a range of other acute and chronic ophthalmological conditions 
(Figure 4).7,27,45–49 Alarge study involving 6,551 OCT scans from 1,370 patients indicated that MMO is transient in over 
80% of cases, so we suggest longitudinal follow-up of patients who exhibit this sign.47 In neuroretinitis, acute subretinal 
fluid and chronic exudates can be effectively visualized by OCT.50  
 
Standard care protocol  
The reviewed evidence suggests that incorporation of OCT findings into the standard care protocol for optic neuritis is 
likely to become routine. However, protocols still have to be validated and to stand the test of time in clinical practice. As 
a minimalistic protocol for standard care, we suggest obtaining two scans using a spectral domain retinal OCT system. 
The proposed scans—a peripapillary ring scan (Figure 2a) and a macular volume scan (Figure 2b)—take 2–5 min per 
eye in patients who can maintain visual fixation. A difference of RNFL values of more than 20% between the two eyes 
may suggest a previous ‘subclinical’ episode. Macular scans should be carefully reviewed for the presence of MMO.47 
 
Research protocol 
All scans should fulfil rigorous established quality control criteria.51,52 A sharp image and high contrast between retinal 
layers is a prerequisite for image post-processing and layer segmentation (Figure 2c). In all cases, we advise acquisition 
of each scan with reference to a stored reference scan taken at baseline, so as to allow long-term follow-up of the 
macular ganglion cell complex analysis and the peripapillary RNFL as sensitive measures for progressive 
neurodegeneration affecting the eye. A range of additional research techniques are available, such as en face OCT, 
polarization-sensitive OCT, adaptive optics, fluorescence labelling, and Doppler OCT.30 
 
Laboratory investigations  
Overview  
It is importan t to note that in most patients with typical MSON, there is no evidence to suggest a need for routine blood 
tests or cerebrospinal fluid (CSF) examination.1 
 
Standard care protocol  
Additional blood investigation is warranted in patients with an atypical presentation, such as lack of pain or severe visual 
loss (<6/60), bilateral visual loss, or severe disc swelling with haemorrhages, and/or with a relevant medical or family 
history. Blood tests can aid identification of conditions such as paraneoplastic optic neuropathy and cancer-associated-
retinopathy. 
 
Metabolic pathology 
In s uspected metabolic conditions, which can be characterized by bilateral and symmetrical visual loss, tests for vitamin 
B12, red blood cell folate and methylmalonic acid levels are recommended.53 Note that low vitamin B12 levels can 
coexist with NMO.54 
 
Systemic pathology  
For suspected systemic disease (see systemic and ischaemic aetiologies in Table 2), tests for haematology, electrolytes, 
liver function, erythrocyte sedimentation rate, C-reactive protein and serum angiotensin-converting enzyme levels are 
advised. 
 
Inflammatory pathology  
Serological studies should be guided by the clinical history. Consideration should be given to syphilis, Lyme disease and 
Bartonella henselae (see infectious aetiologies in Table 2). 
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Immunological pathology 
A resource-saving screening approach to immunological blood tests is to start with antinuclear antibodies (ANA), 
following the international guidelines.55 In cases of ANA seropositivity, particularly in young patients, this test may be 
followed by a more targeted approach that includes assays for autoantibodies against extractable nuclear antigens, 
perinuclear antineutrophil cytoplasmic antibodies, cardiolipin and β2 glycoprotein 1. This approach facilitates the 
detection of autoimmune overlap syndromes, which occur in around 5% of patients with autoimmune disease.56,57 In one 
case, a patient with optic neuritis was found to be seropositive for anti-GQ1b and anti-GT1a IgG.58  
If orbital disease causing a compressive optic neuropathy is suspected, thyroid function and anti-thyroid 
antibody tests should be requested. Tests for anti-CRMP5 (also called anti-CV2) and recoverin autoantibodies should be 
requested in patients with a history of cancer or suspected paraneoplastic disease, in order to identify conditions such as 
cancer-associated retinopathy. In suspected NMO, state-of-the-art assays for AQP4- IgG are recommended because of 
their high diagnostic specificity (>95%) and sensitivity (77%).59–61 Testing for AQP4-IgG is advised in all cases with 
features atypical for MSON—in particular, severe relapsing or bilateral loss of vision—as AQP4-IgG seropositivity has 
specific diagnostic and prognostic implications.62,63 Because of the heterogeneity of assays61 and the possible harmful 
and ethical consequences of a false-negative or false-positive diagnosis of NMO–optic neuritis, we recommend that 
AQP4-IgG detection should be performed in laboratories that use validated assays with high sensitivity and specificity. 
Evidence exists, however, for a subgroup of patients with NMO who are AQP4-IgG seronegative but myelin 
oligodendrocyte glycoprotein IgG seropositive, so AQP4-IgG seronegativity does not necessarily preclude a diagnosis of 
NMO.64,65 
 
Cerebrospinal fluid  
CSF exa mination will occasionally be necessary in patients presenting with symptoms of optic neuritis, principally when 
there is doubt as to the aetiology. CSF examination is rarely contributory in cases deemed to be MSON on other 
criteria.16 The CSF examination should include cytology, total protein, glucose and oligo clonal bands.66 Of note, CSF 
OCBs are not specific for MS, and might also be found in over 30 other conditions. 67 The type 2 OCB pattern, in which 
OCBs are found in the CSF but not in the serum, indicating isolated intrathecal oligoclonal IgG synthesis, is only found in 
about 10% of patients with NMO.68,69 However, CSF glial fibrillary acidic protein (GFAP) levels have a high sensitivity 
(85–100%) but low specificity (77–100%) for acute NMO.70–73 
 
Research protocol 
In view of the emerging body of literature on the role of vitamin D deficiency as a risk factor for demyelination, testing of 
vitamin D levels is becoming increasingly relevant for optic neuritis research.74,75 In addition, blood neurofilament levels 
might be of prognostic value in optic neuritis.76–78 
Standardized sample collection, processing, storage and analyses are mandatory to ensure high-quality 
biomarker research, enable multicentre analyses, make use of historical cohorts, and safeguard against bias.79 
Collection of both plasma and serum is recommended. Samples should be well mixed prior to transport to the laboratory, 
and should be centrifuged at room temperature (2,000 g for 10 min) within 1 h of sampling. In situations where a longer 
interval between sampling and processing can be expected, transport and storage at 4 °C is advised. Some biomarkers 
are sensitive to repeated freeze–thaw cycling, so we advise that each sample should be stored in at least four 500 l 
aliquots at –80 °C.  
We anticipate that the discovery of new autoantibodies, in part through retrospective analysis of stored CSF, 
serum and plasma samples, will be relevant for the differential diagnosis of optic neuritis. 
 
MRI Overview   
This section focuses on MRI of the optic nerves, which is complementary to the well-established literature on brain 
MRI.80 MRI of the optic nerves helps us to rule out alternative diagnoses, demonstrate optic nerve inflammation, and con 
duct research into the assessment of optic nerve damage and atrophy.  
Classic MRI findings in acute optic neuritis are highsignal- intensity lesions in the optic nerve (occasionally 
extending to the chiasm and the optic tracts) on T2-weighted MRI (preferably with fat suppression; Figure 1c). There is 
usually also swelling of the affected segment of the optic nerve. More-extensive optic nerve lesions are associated with 
poor clinical outcomes such as slow and incomplete recovery.81,82  
Depending on the severity of inflammation, contrast enhancement can be observed on (fat-suppressed) T1-
weighted images in about 94% of patients with acute optic neuritis. In established optic atrophy from previous damage, 
T2 high signal changes will also be seen, but these changes are associated with thinning of the nerve and do not change 
over time. Sensitivity of detection of contrast-enhancing lesions in the optic nerve can be further increased by using a 
higher dosage of contrast medium (for example, a triple dose), but in our view this approach is not cost-effective.83,84  
Patients with NMO have a propensity towards extensive involvement of the anterior visual pathways, and of the 
intracranial as opposed to the intraorbital segments, making these individuals particularly prone to chiasmitis and 
simultaneous bilateral disease.85,86 
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Standard care protocol  
No consensus guidelines have been formulated on how and when to perform optic nerve MRI in cases of optic neuritis. 
For assessment of the optic nerve, the MRI protocol must include fat-suppressed T2-weighted images (for example, 
short tau inversion recovery or frequency-specific selective partial inversion recovery)81 and contrast- enhanced (fat-
suppressed) T1-weighted images (Box 3). The most cost-effective approach is to use a standard dosage of gadolinium-
based contrast medium.  
T1-weighted and T2-weighted sequences for the assessment of the whole orbit and brain are useful to 
simultaneously detect possible demyelinating brain lesions. For the best spatial resolution, images should be acquired 
without any interslice gap. The spatial resolution should be 3 mm slice thickness, in plane 1 × 1 mm (measured voxel 
size 3 × 1 × 1 mm). Additional sagittal proton density-weighted/T2-weighted (preferably spin echo) and T1-weighted post-
contrast images of the spinal cord are useful for detecting demyelinating spinal cord lesions and for differential diagnostic 
purposes (Box3). Further radiological tests to exclude vascular malformations or vasculitis may be indicated, as 
summarized in Table 2. 
 
Research protocol  
Although MRI at higher magnetic field strengths (for example, 3 T) does not necessarily lead to an earlier diagnosis of 
MS, it does result in a higher image quality.87,88 In general, a standard head coil is sufficient for the assessment of the 
orbit and the optic nerves. However, surface coils focusing on the orbit may further improve the image quality.89  
Important MRI methods for research purposes include measures of optic nerve atrophy obtained using highresolution 3D 
T2-weighted sequences,90 quantitative MRI techniques91 and diffusion tensor imaging.92 These advanced techniques 
can assist in the early detection of clinical impairment, and enable quantitative estimation of the presence and extent of 
damage to the optic nerve.93,94 These measures have all been proposed as markers of irreversible tissue damage and 
disease progression, and as predictors of clinical recovery. 
 
Electrodiagnostic tests  
Overview 
Electrodiagnostic tests have a role in the investigation of atypical presentations of optic neuritis.95 The tests should not 
be limited to visual evoked potentials (VEPs), as any retinal abnormality will affect the VEP signal.95,96 Indeed, the 
International Society for Clinical Electrophysiology of Vision (ISCEV) standards97 recommend that in cases of 
unexplained visual loss, the VEP results should be interpreted in conjunction with both a standard electroretinogram 
(ERG) and a pattern electroretinogram(PERG).98 
 
Standard care protocol  
The ISCEV standards97 state that electrophysiological tests are of little diagnostic value in acute retrobulbar optic 
neuritis, but may be useful in studies evaluating therapy. If the diagnosis is uncertain, however, a full series of 
electrophysiological tests should be performed, as outlined below. 
 
Visual evoked potentials 
The VEP represents a specific change in an ongoing EEG recording due to the response of the visual pathway to either 
a pattern or a flash stimulus. VEPs have been shown to be a highly sensitive but not especially specific test for optic 
neuritis. A unilateral substantially delayed VEP with minimal amplitude reduction is highly suggestive of a demyelinating 
optic neuropathy, for example, recovered MSON or subclinical involvement of the optic nerve in MS. VEP abnormalities 
will also be seen in patients with refractive errors, pure retinal dysfunction, compressive lesions of the optic nerve, 
Parkinson disease99 or migraine.100 Normality of both the ERG and VEP supports the differential diagnosis of non-
organic aetiology if performed after other investigations failed to yield a diagnosis. 
 
Electroretinography  
An ERG provides diagnostic information about the rod and cone photoreceptors, and inner retinal function across the 
entire retina. The differential diagnosis of a pale optic disc with reduced central vision includes cone dystrophies and 
maculopathies, which will be incorrectly diagnosed if VEPs are used alone. 
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Research protocol  
Multifocal VEPs allow fine mapping of the electrophysiological abnormalities in the visual pathway. This mapping enables 
detection of abnormalities restricted to specific topographies, and may be more sensitive than standard VEPs.  
As the macula comprises less than 5% of the retina, a maculopathy will generally not affect the full-field ERG. 
The PERG stimulus parameters mean that the macula is the retinal location that is primarily stimulated.96 The PERG is a 
surrogate test of macular function, and can, therefore, be used to differentiate macular from optic nerve causes of central 
vision loss. The two main components of the PERG are N95 and P50,96,101,102 and the N95 component and N95:P50 ratio 
were found to be useful in optic neuritis.101–104 The optic nerve head component responses of multifocal ERG may also 
emerge as a useful tool in the assessment of optic neuritis.105 
 
Perimetry Overview 
The classic visual field defect described in MSON is a central scotoma with a sloping border of the isopters.106 Of note, 
however, this feature has only been reported in 2% of cases,107 and becomes even rarer (0.5%) later in the disease 
course. Most patients experience a more generalized reduction in their visual field sensitivity (66%).107 By contrast, 
altitudinal visual field defects suggest a vascular differential diagnosis,108 and sparing of central vision suggests an optic 
perineuritis,109 but neither pattern will rule out optic neuritis. 
Automated perimetry should be performed using threshold estimation strategies.110,111 An important limitation, 
particularly in neurological conditions, children or elderly patients, is that the test is time-consuming and the failure rate 
may be up to 46%.112–114 One needs to consider operator instruction effects, ‘natural variation’ in test results, and 
learning effects.115,116 It may not be possible to detect a visual field defect until about 25–35% of retinal ganglion cells 
have been lost.117–119 Therefore, as a consensus, we hesitate to recommend perimetry as a mandatory part of a standard 
care protocol but, rather, advocate selective use in cases where the test results may guide the differential diagnosis 
(Table 2), or in the presence of red flags (Box 1). 
 
Research protocol  
Given that production of the Goldmann perimeter has stopped and experience is vanishing, we recommend use of 
standard threshold automated perimetry. The stimulus size should be Goldmann No. III (0.481°). A visual field of 20–30° 
should suffice (24-2 or 30-2 protocols on the Humphrey Zeiss perimeter; full threshold 32 or static white-on-white fields 
on the Octopus 900 series). 
 
Conclusions and further perspectives  
The clinical spectrum of optic neuritis has broadened over the past two decades. This development was driven by 
several factors: cumulative experience from trials on treatment of optic neuritis; clinical recognition of a divergent 
semiology; discovery of new autoantibodies and biomarkers; and availability of new high-resolution imaging techniques 
for the optic nerve and retina. 
A need exists to make use of this knowledge and these techniques to better investigate and define the clinical 
spectrum of optic neuritis with the aim of guiding future patient management. Importantly, some forms of optic neuritis 
(for example, NMO and CRION) will require rigorous immunosuppression to protect patients from blindness. It is also 
essential that patients with these conditions are not included in MSON treatment trials. We anticipate that the 
investigation protocol presented here will help us to reach a consensus on the classification of optic neuritis and how to 
optimize treatment. This consensus should, in turn, be pursued internationally so that different approaches can be 
validated in those parts of the world where MS is less common.  
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Key points 
 Optic neuritis is frequently but not always associated with multiple sclerosis (MS), and patients who present with 
optic neuritis will want to know about their risk of developing MS 
 
 Early recognition of optic neuritis not caused by MS is important to prevent severe visual loss, and to avoid 
inappropriate use of MS-targeted treatments 
 
 No international consensus exists on the nosology of optic neuritis: the aetiology remains idiopathic in many cases, 
and attempts at classification fall short, in part because we lack a uniform investigation protocol 
 
 This Review on established and emerging diagnostic tools proposes a consensus on the investigation of patients 
with suspected optic neuritis in both standard care and research 
 
 The aims are to aid recognition of patients at risk of severe visual loss, to contribute to future attempts at 
classification of optic neuritis, and to provide end points for clinical studies 
 
 
Box 1 | Red flags implying diagnosis other than MSON 
A typical clinical presentation 
  Pain or loss of vision presenting for more than 2 weeks 
  Absence of pain 
  Retinal abnormalities 
  Unexplained optic atrophy 
  Severe loss of vision in patients with a non-white ethnic background 
  Severe loss of vision without early recovery 
 
Atypical course 
 Progressive loss of vision 
 Absence of recovery for more than 3 months 
 Worsening of visual function after reducing or stopping steroids or immunosuppression 
 
Bilateral optic neuritis* 
Past medical history of cancer 
 
*Simultaneous binocular visual loss must be distinguished from sequential bilateral visual loss. Both visual acuity and 
visual field need to be documented; sole assessment of visual acuity may miss a peripheral visual field defect. 
Abbreviation: MSON, multiple sclerosis-associated optic neuritis. 
 
Box 2 | A case of relapsing isolated optic neuritis 
A 35-year-old woman presented with blurred vision in her right eye for the second time in 3 months. Visual loss was 
preceded by several days with photopsia, but no pain on eye movements was reported. Uncorrected visual acuity in the 
right eye was 0.03 with a central scotoma. Oligoclonal bands were detected in the cerebrospinal fluid (CSF), and 
additional identical oligoclonal bands (OCBs) were found in CSF and serum (‘type 3’ or mirror plus pattern67). CSF white 
cell count was elevated (25 per mm3), with a normal total protein level (19 mg/l). The test for anti-aquaporin 4 antibodies 
was negative, as were the remaining autoimmune, infectious and metabolic laboratory investigations.  
 
Fundus photography (Figure 1a) showed that the right optic disc was pale temporally, indicating optic atrophy, 
whereas the left optic disc was normal. Fluorescein angiography (Figure 1b) indicated normal retinal blood flow and 
absence of leakage. Short tau inversion recovery MRI (Figure 1c) demonstrated an increased signal in the right optic 
nerve, indicating inflammation. 
 
The patient received intravenous steroids according to the optic neuritis treatment trial protocol, but her vision 
failed to improve over the subsequent 9 months. Serial optical coherence tomography measurements demonstrated the 
development of further peripapillary retinal nerve fibre layer (pRNFL) atrophy. Consistent with the photograph of the right 
optic disc, some pRNFL atrophy of the temporal nerve fibres was observed (thin black line in Figure 1d). Atrophy of the 
pRNFL progressed over the subsequent 9 months and mainly affected the temporal fibres. Automated layer 
segmentation (Figure 1e - h) demonstrated only a very small degree of atrophy in the inner plexiform layer and inner 
nuclear layer. By contrast, more-global thickening developed in the outer retinal layers (Figure 1h). This is a consistent 
finding in the literature, but its significance is unknown. 
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Box 3 | MRI protocol 
Optic nerve (~10 min) 
 Coronal T2-weighted images with fat suppression (for example, short tau inversion recovery or frequency-specific 
selective partial inversion recovery) 
 Coronal T1-weighted images before and after contrast administration 
 
Brain (~20 min)* 
 Axial proton density-weighted/T2-weighted 
Sagittal fluid-attenuated inversion recovery (preferably 3D) 
 Axial T1-weighted after contrast administration 
 
Spinal cord (~15 min)‡ 
 Sagittal proton density-weighted/T2-weighted 
 Sagittal T1-weighted after contrast administration 
 
Research 
 High-resolution 3D T2-weighted (CISS) images for visualization and volume measurements of the optic nerve 
 Diffusion tensor imaging 
 
*For suspected demyelination in the brain (for example, multiple sclerosis). ‡For suspected demyelination of the spinal 
cord (for example, neuromyelitis optica). 
 
 
Tables and figures 
 
 
 
 
*To demonstrate an isolated episode of optic neuritis, relevant pathology elsewhere in the CNS must be excluded. ‡The 
assessor should be pragmatic and allow for occasional nonspecific MRI lesions, which tend to become increasingly 
frequent as magnetic field strength and resolution increase. Abbreviation: AQP4-IgG, anti-aquaporin 4 antibodies. 
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*Sinusitis was high up in the differential diagnosis in the past but has almost disappeared over the past few decades.122 It 
is absolutely mandatory to obtain a good history including recent travels to high-risk areas for certain infections (malaria, 
dengue virus, West Nile virus, cysticercosis) or other forms of exposure. §A macular star is suggestive of neuroretinitis 
and can be associated with peripheral retinal haemorrhages and speckled appearance of the pigment epithelium. 
||Endemic optic neuropathies have been described in Cuba and Tanzania. Abbreviations: ACE, angiotensin-converting 
enzyme; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; AZOOR, acute zonal occult outer 
retinopathy; CCF, carotid cavernous sinus fistula; CRP,c-reactive protein; CSF, cerebrospinal fluid; CTA, CT 
angiography; DSA, digital subtraction angiography; ECG, electrocardiogram; ERG, electroretinogram; ESR, erythrocyte 
sedimentation rate; GCA, giant cell arteritis; LHON, Leber hereditary optic neuropathy; MMA, methylmalonic acid; MRA, 
magnetic resonance angiography; OCT, optical coherence tomography; PION, posterior ischaemic optic neuropathy; 
SLE, systemic lupus erythematosus; VEP, visual evoked potentials. 
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 Figure 2 | Minimal retinal OCT protocol—part I: peripapillary ring scan. A 27-year-old woman experienced two 
episodes of NMO-ON in her left eye. Visual acuity in the left eye was ‘no light perception’ after the first episode of 
NMO-ON. The second episode started with pain on eye movements, but visual acuity was not helpful for clinical 
monitoring. a | Peripapillary ring scan (green circle in SLO image). b | Corresponding OCT B-scan. Distance 
between the red line (inner limiting membrane) and the horizontal green line indicates RNFL thickness. Vertical 
green line indicates the corresponding anatomical position in the SLO image. c | Thin black line indicates reference 
RNFL thickness after the first episode of NMO-ON and thick black line indicates additional RNFL loss manifesting 3 
months after the second episode of NMO-ON. Abbreviations: INF, inferior; NAS, nasal; NMO-ON, neuromyelitis 
optica–optic neuritis; OCT, optical coherence tomography; RNFL, retinal nerve fibre layer; SLO, confocal scanning 
laser ophthalmoscopy; SUP, superior; TMP, temporal. 
Figure 1 | Ophthalmological and MRI investigations in a 35-year-old woman with blurred vision in the right eye. a | 
On fundus photographs, the right optic disc (top image) was pale temporally, whereas the left optic disc (bottom 
image) was normal. b | Fluorescein angiography was normal. c | Coronal section of a fat-suppressed MRI STIR 
sequence of the orbit demonstrates an increased signal in the right optic nerve. d | Optical coherence tomography 
shows pRNFL atrophy of the temporal nerve fibres (thin black line at baseline, thick black line at 9-month follow-
up). Yellow and red areas indicate atrophy; green area describes the normal thickness profile around the optic 
disc; blue and purple areas indicate pRNFL thickening. Vertical green line shows the reference position in the 
corresponding confocal scanning laser ophthalmoscopy image (not shown). e | Automated layer segmentation 
demonstrated a small degree of atrophy (green areas) in the IPL and f | INL. g | Extent and location of atrophy is 
best appreciated by summation of the inner retinal layers (pRNFL, IPL and INL). h | More-global thickening 
developed in the outer retinal layers (outer plexiform layer to basal membrane; red area in summation graph). 
Abbreviations: INF, inferior; INL, inner nuclear layer; IPL, inner plexiform layer; NAS, nasal; pRNFL, peripapillary 
retinal nerve fibre layer; SUP, superior; TMP, temporal. 
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Figure 3 | Minimal retinal OCT protocol—part II: macular volume scan. Scans are from a 27-year-old woman who 
experienced two episodes of NMO-ON in her left eye (same patient as in Figure 2). a,b | Macular volume scan 
showing the confocal scanning laser ophthalmoscopy image. Thin green lines indicate the entire volume scan and 
bold green line indicates the OCT B-scan through the foveola. Thickness maps for c | retinal nerve fibre layer, d | 
GCC, e | all inner retinal layers combined and f | total retinal thickness. g,h | Atrophy of the macular region 
following the second episode of NMO-ON. Each panel shows reference scan (top), scan 3 months after the 
second episode of NMO-ON (middle), and difference between the two scans (bottom; red areas indicate 
increased thickness and green areas indicate further atrophy). Atrophy is less visible in the total retinal thickness 
scans (part g), but is pronounced in the GCC scans (part h). Abbreviations: GCC, ganglion cell complex; NMO-
ON, neuromyelitis optica–optic neuritis; OCT, optical coherence tomography; RNFL, retinal nerve fibre layer. 
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Table1: Tabellenüberschrift steht in der obersten (nicht eingerahmten) Zeile. 
 Spalte 1 Spalte 2 Spalte 3 
Zeile 1 Wert 1.1 Wert 2.1 Wert 3.1 
Zeile 2 Wert 1.2 Wert 2.2 Wert 3.2 
Zeile 3 Wert 1.3 Wert 2.3 Wert 3.3 
 
 
Figure 4 | MMO in a 44-year-old man with Harding disease (multiple sclerosis plus Leber hereditary optic 
neuropathy). 15 years earlier, he experienced an episode of optic neuritis in his left eye. Left optic disc was 
pale with severe atrophy of the peripapillary retinal nerve fibre layer (global average 42 μm). a | MMO in the 
perimacular rim of the left eye (see also Supplementary Video 1 online). b | Inset magnified to show retinal 
layer cytoarchitecture. A retinal ganglion cell is drawn in yellow; the INL, where MMO resides, contains bipolar 
cells (magenta), horizontal cells (light blue) and amacrine cells (dark blue). Bipolar cells synapse with rods 
(pink) and cones (red) located in the outer retina. Müller cells (green) traverse all retinal layers. c | MMO may 
be attributable to persistent microcystic changes of the INL, probably following bidirectional trans-synaptic 
axonal degeneration (anterograde: from outer retina to brain; retrograde: from brain to eye). d | The transient 
nature of MMO has been related to traction at the vitreoretinal interface (arrow), and is proposed to reflect 
signs of inflammation from breakdown of the blood–retina barrier, microglial activation, presence of 
autoantibodies against AQP4 or KIR4.1, and/or Müller cell pathology. Abbreviations: AQP4, aquaporin 4; INL, 
inner nuclear layer; MMO, microcystic macular oedema.  
